University of Sheffield, Academic Unit of Reproductive and Developmental Medicine, Jessop Wing, Royal Hallamshire Hospital, Sheffield S10 2SF, United Kingdom.
J Clin Endocrinol Metab. 2010 Dec;95(12):5144-54. doi: 10.1210/jc.2010-0701.
Development of novel antibodies directed against anti-Müllerian hormone (AMH) has allowed measurement in serum and immunohistochemical assessment in tissues. AMH is secreted by granulosa cells in late preantral and small antral follicles and appears in serum in detectable and stable amounts throughout the menstrual cycle. AMH measurement allows an assessment of ovarian reserve with several advantages over other biochemical and biophysical markers. Recent research has highlighted utility in cases of premature ovarian failure, either iatrogenic after treatment for cancer, or naturally occurring, in polycystic ovary syndrome and in the management of superovulation in assisted reproduction. A surge in research activity has taken place over the last 5 yr, and the true place of AMH in reproductive medicine remains to be fully elucidated, but the rapid and widespread adoption of AMH assay into clinical practice demonstrates the degree of interest in this new marker amongst reproductive endocrinologists.
新型抗苗勒管激素（AMH）抗体的开发使得 AMH 能够在血清中进行测量，并在组织中进行免疫组织化学评估。AMH 由窦前卵泡和小窦卵泡的颗粒细胞分泌，在整个月经周期中以可检测和稳定的量出现在血清中。AMH 测量法可评估卵巢储备功能，与其他生化和生物物理标志物相比具有多项优势。最近的研究强调了其在卵巢早衰中的应用，包括癌症治疗后的医源性卵巢早衰，以及多囊卵巢综合征和辅助生殖中超排卵的自然发生的卵巢早衰。在过去的 5 年中，研究活动急剧增加，AMH 在生殖医学中的真正地位仍有待充分阐明，但 AMH 检测法迅速广泛地应用于临床实践，表明了生殖内分泌学家对这种新标志物的浓厚兴趣。
